IL136131A0 - Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotype - Google Patents
Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotypeInfo
- Publication number
- IL136131A0 IL136131A0 IL13613198A IL13613198A IL136131A0 IL 136131 A0 IL136131 A0 IL 136131A0 IL 13613198 A IL13613198 A IL 13613198A IL 13613198 A IL13613198 A IL 13613198A IL 136131 A0 IL136131 A0 IL 136131A0
- Authority
- IL
- Israel
- Prior art keywords
- sup
- rpos
- phenotype
- recombinant vaccines
- attenuated bacteria
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0006—Contraceptive vaccins; Vaccines against sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/22—Processes using, or culture media containing, cellulose or hydrolysates thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/879—Salmonella
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/886—Streptomyces
- Y10S435/897—Streptomyces griseus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/970,789 US6024961A (en) | 1997-11-14 | 1997-11-14 | Recombinant avirulent immunogenic S typhi having rpos positive phenotype |
PCT/US1998/024295 WO1999025387A1 (en) | 1997-11-14 | 1998-11-13 | Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotype |
Publications (1)
Publication Number | Publication Date |
---|---|
IL136131A0 true IL136131A0 (en) | 2001-05-20 |
Family
ID=25517522
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL13613198A IL136131A0 (en) | 1997-11-14 | 1998-11-13 | Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotype |
Country Status (12)
Country | Link |
---|---|
US (3) | US6024961A (da) |
EP (1) | EP1030690B1 (da) |
JP (1) | JP2001523649A (da) |
KR (1) | KR20010024650A (da) |
AT (1) | ATE219948T1 (da) |
AU (1) | AU736242B2 (da) |
CA (1) | CA2309925C (da) |
DE (1) | DE69806408T2 (da) |
DK (1) | DK1030690T3 (da) |
ES (1) | ES2181306T3 (da) |
IL (1) | IL136131A0 (da) |
WO (1) | WO1999025387A1 (da) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE312934T1 (de) * | 1995-06-07 | 2005-12-15 | Univ Washington | Rekombinant bakterielle system mit umweltbeschränkte lebensfähigkeit |
US6024961A (en) * | 1997-11-14 | 2000-02-15 | Washington University | Recombinant avirulent immunogenic S typhi having rpos positive phenotype |
US6585975B1 (en) | 1998-04-30 | 2003-07-01 | Acambis, Inc. | Use of Salmonella vectors for vaccination against helicobacter infection |
NZ512730A (en) * | 1998-12-04 | 2003-12-19 | Univ Manitoba | A immunization procedure against chlamydia infection using an attenuated bacteria comprsing a plasmid with a major outer membrane protein (MOMP) from chlamydial |
JP3655510B2 (ja) * | 1999-10-29 | 2005-06-02 | 株式会社東芝 | ネットワーク接続装置、通信装置及びネットワーク接続方法 |
EP1226254A2 (en) * | 1999-11-05 | 2002-07-31 | L'Unité de Recherche en Biologie Moléculaire (URBM) des Facultés Universitaires Notre Dame de la Paix (FUNDP) | Virulence genes, proteins, and their use |
US6207167B1 (en) * | 1999-12-09 | 2001-03-27 | Crystal Biotechnology Research And Development Co., Ltd. | Chicken leucocytozoon vaccine |
DK1272213T3 (da) * | 2000-04-06 | 2006-07-10 | Seer Pharmaceuticals Llc | Mikrobielt afgivelsessystem |
US6780405B1 (en) | 2000-04-28 | 2004-08-24 | Avant Immunotherapeutics, Inc. | Regulated antigen delivery system (RADS) |
US20030138769A1 (en) * | 2000-08-16 | 2003-07-24 | Birkett Ashley J. | Immunogenic HBc chimer particles having enhanced stability |
US6872547B1 (en) * | 2000-10-11 | 2005-03-29 | Washington University | Functional balanced-lethal host-vector systems |
US20040137003A1 (en) * | 2001-04-30 | 2004-07-15 | Curtiss Iii Roy | Regulated antigen delivery system (rads) |
US20030175863A1 (en) * | 2001-08-15 | 2003-09-18 | Birkett Ashley J. | Influenza immunogen and vaccine |
US20030185858A1 (en) * | 2001-08-15 | 2003-10-02 | Birkett Ashley J. | Immunogenic HBc chimer particles stabilized with an N-terminal cysteine |
US7361352B2 (en) * | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
US20050096283A1 (en) * | 2001-12-14 | 2005-05-05 | The Regents Of University Of California | Methods of inhibiting fertility |
US20040043003A1 (en) * | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
US20050075298A1 (en) * | 2002-01-31 | 2005-04-07 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa |
US20040009937A1 (en) * | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
US7351413B2 (en) * | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
EP2380440B1 (en) | 2002-04-15 | 2016-03-09 | Washington University | Regulated attenuation of live vaccines to enhance cross protective immunogenicity |
US7270961B2 (en) * | 2002-04-16 | 2007-09-18 | Hui Sunny Chang | In vitro assay for quantitating secreted antibodies in lymphocyte supernatant for evaluation of vaccine or antigen induced specific antibody secretion from ex vivo circulating antibody-secreting lymphocytes |
US20050220818A1 (en) * | 2002-06-21 | 2005-10-06 | Wellstat Biologics Corporation | Administration of therapeutic viruses |
DE10326187A1 (de) * | 2003-06-06 | 2005-01-05 | MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH | Zellen als Träger für Bakterien |
US7390646B2 (en) * | 2003-09-17 | 2008-06-24 | The Regents Of The University Of California | Bacterial vectors and methods of use thereof |
CN102078622A (zh) | 2004-08-13 | 2011-06-01 | 巴里.J.马沙尔 | 细菌递送系统 |
US8029777B2 (en) * | 2004-08-13 | 2011-10-04 | Marshall Barry J | Helicobacter system and uses thereof |
AU2007239095B2 (en) | 2006-01-09 | 2012-05-03 | The Regents Of The University Of California | Immunostimulatory combinations for vaccine adjuvants |
WO2007106073A2 (en) | 2006-03-02 | 2007-09-20 | University Of Massachusetts | Modified pathogens for use as vaccines |
KR100749493B1 (ko) * | 2006-03-22 | 2007-08-14 | 한국원자력연구원 | 대장균에서 rpoS 유전자의 발현을 조절함으로서프로피온산에 대한 미생물 감수성을 증진시키는 방법 |
US20080124355A1 (en) | 2006-09-22 | 2008-05-29 | David Gordon Bermudes | Live bacterial vaccines for viral infection prophylaxis or treatment |
EP2150616A4 (en) | 2007-05-10 | 2011-07-27 | Univ Arizona | REGULATED ANTIGEN SYNTHESIS AND / OR REGULATED ATTENUATION FOR IMPROVING VACCINATE IMMUNOGENICITY AND / OR SAFETY |
EP2152883A4 (en) * | 2007-05-10 | 2010-10-27 | Univ Arizona | RECOMBINANT BACTERIA COMPRISING VECTORS FOR THE EXPRESSION OF NUCLEIC ACID SEQUENCES ENCODING ANTIGENS |
ES2323839B2 (es) * | 2007-07-24 | 2010-07-08 | Universidad Complutense De Madrid | Cepa viva atenuada de salmonella enterica serovar choleraesuis como vacuna y vehiculo vacunal para el ganado porcino. |
US8465755B2 (en) * | 2007-10-05 | 2013-06-18 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting an immune response against enteric pathogens |
WO2009062034A1 (en) * | 2007-11-07 | 2009-05-14 | Auburn University | Methods, compositions, and sequences of zp-binding peptides for immunocontraception of dogs and other animals |
ES2394035T3 (es) * | 2008-04-07 | 2013-01-15 | Auburn University | Métodos para inmunocontracepción específica para ciertas especies de animales |
EP2294090B1 (en) * | 2008-06-03 | 2014-05-14 | University of Maryland, Baltimore | NON-HEMOLYTIC ClyA FOR EXCRETION OF PROTEINS |
WO2010045620A1 (en) * | 2008-10-17 | 2010-04-22 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae |
US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
US9163219B2 (en) * | 2009-04-14 | 2015-10-20 | Arizona Board Of Regents On Behalf Of Arizona State University | Single expression vector for generation of a virus with a segmented genome |
GB2483595B (en) | 2009-05-22 | 2017-03-29 | The Arizona Board Of Regents For And On Behalf Of Arizona State Univ | Recombinant bacterium and methods of antigen and nucleic acid delivery |
US9045742B2 (en) * | 2009-05-29 | 2015-06-02 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant Edwardsiella bacterium |
US9062297B2 (en) | 2010-01-13 | 2015-06-23 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Yersinia pestis vaccine |
WO2011091291A1 (en) | 2010-01-22 | 2011-07-28 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | BACTERIUM COMPRISING A REGULATED rfaH NUCLEIC ACID |
WO2011119595A1 (en) | 2010-03-22 | 2011-09-29 | Auburn University | Phage constructs, sequences and antigenic compositions for immunocontraception of animals |
US9598697B2 (en) | 2010-05-28 | 2017-03-21 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Recombinant bacterium to decrease tumor growth |
US20120156215A1 (en) | 2010-06-21 | 2012-06-21 | Auburn University | Phage-GnRH Constructs, Their Mimics, Antigenic Compositions, and Sequences for Immunocontraception of Animals and Other Applications |
WO2012003460A2 (en) | 2010-07-02 | 2012-01-05 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Compositions and methods for bacterial lysis and neutral lipid production |
US8940297B2 (en) | 2010-12-22 | 2015-01-27 | Saint Louis University | Expression of thrombin variants |
MX363465B (es) | 2011-02-18 | 2019-03-25 | Kythera Biopharmaceuticals Inc | Tratamiento de la grasa submental. |
US9303264B2 (en) | 2012-05-18 | 2016-04-05 | The Arizona Board Of Regents For And On Behalf Of Arizona State University | Photosynthetic microorganisms expressing thermostable lipase |
US9580718B2 (en) | 2013-06-17 | 2017-02-28 | Arizona Board Of Regents On Behalf Of Arizona State University | Attenuated live bacteria with increased acid resistance and methods of use thereof |
US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
CN106222123B (zh) * | 2016-07-29 | 2019-06-07 | 扬州大学 | 鸡白痢沙门菌三基因敲除减毒突变株制备及其应用 |
US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
WO2019014398A1 (en) | 2017-07-11 | 2019-01-17 | Actym Therapeutics, Inc. | MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF |
JP7340591B2 (ja) | 2018-07-11 | 2023-09-07 | アクティム・セラピューティクス・インコーポレイテッド | 遺伝子操作された免疫刺激性細菌菌株およびその使用 |
US11242528B2 (en) | 2018-08-28 | 2022-02-08 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
CN110157723B (zh) * | 2019-05-10 | 2021-10-01 | 四川大学 | 一步同源重组法在鼠伤寒沙门菌必须基因敲除中的应用 |
WO2021062037A1 (en) | 2019-09-24 | 2021-04-01 | Auburn University | Phage-peptide constructs for stimulation of an anti-cancer immune response against cd47 |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
KR20240015037A (ko) * | 2022-07-25 | 2024-02-02 | 충남대학교산학협력단 | Vc1 분비를 위한 재조합 발현 벡터 및 이로 형질전환된약독화 살모넬라 균주 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4837151A (en) * | 1980-05-19 | 1989-06-06 | The Board Of Trustees Of The Leland Stanford Junior University, Stanford University | Live vaccines comprising two mutations and foreign antigen |
US5294441A (en) * | 1987-06-04 | 1994-03-15 | Washington University | Avirulent microbes and uses therefor: salmonella typhi |
IL86583A0 (en) * | 1987-06-04 | 1988-11-15 | Molecular Eng Ass | Vaccine containing a derivative of a microbe and method for the production thereof |
US5387744A (en) * | 1987-06-04 | 1995-02-07 | Washington University | Avirulent microbes and uses therefor: Salmonella typhi |
WO1989003427A1 (en) * | 1987-10-07 | 1989-04-20 | Washington University | A method of maintaining a desired recombinant gene in a genetic population of cells |
CA2096529C (en) * | 1990-11-21 | 2003-01-21 | Roy Curtiss, Iii | Recombinant avirulent salmonella antifertility vaccines |
WO1994024291A2 (en) * | 1993-04-15 | 1994-10-27 | Washington University | Compositions of antigen containing recombinant salmonella, their use in anti-malarial vaccines and method for their preparation |
EP0705108A4 (en) * | 1993-06-02 | 1997-08-06 | Tvw Telethon Inst Child Health | USE OF CRYPTIC PEPTIDES FOR INDUCTION IMMUNOLOGICAL TOLERANCE |
US6024961A (en) * | 1997-11-14 | 2000-02-15 | Washington University | Recombinant avirulent immunogenic S typhi having rpos positive phenotype |
-
1997
- 1997-11-14 US US08/970,789 patent/US6024961A/en not_active Expired - Lifetime
-
1998
- 1998-11-13 AU AU14595/99A patent/AU736242B2/en not_active Expired
- 1998-11-13 DK DK98958581T patent/DK1030690T3/da active
- 1998-11-13 ES ES98958581T patent/ES2181306T3/es not_active Expired - Lifetime
- 1998-11-13 WO PCT/US1998/024295 patent/WO1999025387A1/en not_active Application Discontinuation
- 1998-11-13 CA CA2309925A patent/CA2309925C/en not_active Expired - Lifetime
- 1998-11-13 EP EP98958581A patent/EP1030690B1/en not_active Expired - Lifetime
- 1998-11-13 KR KR1020007005297A patent/KR20010024650A/ko not_active Application Discontinuation
- 1998-11-13 DE DE69806408T patent/DE69806408T2/de not_active Expired - Lifetime
- 1998-11-13 AT AT98958581T patent/ATE219948T1/de not_active IP Right Cessation
- 1998-11-13 IL IL13613198A patent/IL136131A0/xx unknown
- 1998-11-13 JP JP2000520820A patent/JP2001523649A/ja active Pending
-
1999
- 1999-05-18 US US09/314,062 patent/US6383496B1/en not_active Expired - Lifetime
-
2002
- 2002-05-03 US US10/138,239 patent/US7083794B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20030031683A1 (en) | 2003-02-13 |
EP1030690B1 (en) | 2002-07-03 |
AU1459599A (en) | 1999-06-07 |
DK1030690T3 (da) | 2002-10-21 |
JP2001523649A (ja) | 2001-11-27 |
US6024961A (en) | 2000-02-15 |
AU736242B2 (en) | 2001-07-26 |
DE69806408D1 (de) | 2002-08-08 |
KR20010024650A (ko) | 2001-03-26 |
ATE219948T1 (de) | 2002-07-15 |
DE69806408T2 (de) | 2003-02-27 |
CA2309925A1 (en) | 1999-05-27 |
ES2181306T3 (es) | 2003-02-16 |
US6383496B1 (en) | 2002-05-07 |
WO1999025387A1 (en) | 1999-05-27 |
EP1030690A1 (en) | 2000-08-30 |
US7083794B2 (en) | 2006-08-01 |
CA2309925C (en) | 2010-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL136131A0 (en) | Recombinant vaccines comprising immunogenic attenuated bacteria having rpos positive phenotype | |
Saxena et al. | Pre-existing immunity against vaccine vectors–friend or foe? | |
GR3035050T3 (en) | Method of preparing a viral vector by homologous intermolecular recombination | |
US10030054B2 (en) | Campylobacter immunogenic compositions and uses thereof | |
WO1998056901A3 (en) | Live attenuated vaccines | |
AU2785089A (en) | Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus | |
CY1107950T1 (el) | Νεϊσσεριακες συνθεσεις εμβολιου και μεθοδοι | |
MY150893A (en) | Recombinant mva virus expressing dengue virus antigens, and the use thereof in vaccines | |
PL343246A1 (en) | Bacteria attenuated by a non-reverting mutation in each of the aroc, ompf and ompc genes, useful as vaccines | |
AU2002217043A1 (en) | Salmonella vaccine | |
Wang et al. | Optimization of antitumor immunotherapy mediated by type III secretion system-based live attenuated bacterial vectors | |
WO2002064757A3 (en) | Influenza viruses with enhanced transcriptional and replicational capacities | |
ATE268384T1 (de) | Analog von haemophilus hin47 mit verminderter protease aktivität | |
Qimron et al. | Identification of Salmonella typhimurium genes responsible for interference with peptide presentation on MHC class I molecules: Δyej Salmonella mutants induce superior CD8+ T‐cell responses | |
ZA985393B (en) | Clostridium perfringens vaccine | |
Khare et al. | SARS-CoV-2 vaccines: types, working principle, and its impact on thrombosis and gastrointestinal disorders | |
TR200002974T2 (tr) | Bruselloza karşı canlı aşı | |
CY1107560T1 (el) | Ζωντανα εξασθενημενα βακτηρια για χρηση σε εμβολιο | |
Atkins et al. | Recombinant Salmonella vaccines for biodefence | |
RS75604A (en) | Microorganismus as carriers of nucleotide sequences coding for cell antigens used for the treatment of tumors | |
YU49995A (sh) | Polinukleotidna vakcina za virus herpesa | |
GB2331521A (en) | Vaccine preparations | |
Wang et al. | Construction, identification, and immunogenic assessments of an HSV-1 mutant vaccine with a UL18 deletion | |
IL67818A0 (en) | Vaccines comprising ozone inactivated organisms and their production | |
AU2018200081B2 (en) | Avirulent, immunogenic flavivirus chimeras |